1. Al-Sarraf M, Martz K, Herskovic A et al.: Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 15 (1997) 277.
2. Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 393 (2019) 1948–1957.
3. Bang YJ, Van Cutsem E, Feyereislova A et al.: ToGA Trial Investigators (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 276(9742) 687–697. Epub 2010 Aug 19. Erratum in: Lancet 376(9749) 1302.
4. Bosset JF, Gignoux M, Triboulet JP et al.: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337 (1997) 161.
5. Cunningham D, Allum WH, Stenning SP et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355 (2006) 11.